EGFR and hepatocellular carcinoma: Modification of nanomedicines with the scAb-EGFR significantly improved the efficiency of delivering nanomedicines into HCC cells overexpressing EGFR on cell membrane, based on which we not only identified PBOV1 as an important oncogene in HCC, but also revealed its molecular mechanisms to affect growth and metastasis of HCC.